ERBB2 and breast cancer: A phase II single arm study of capecitabine and pembrolizumab in patients with HER2-negative advanced breast cancer reported that the combination was well tolerated, and most observed adverse events were low grade and consistent with what would be expected with capecitabine monotherapy75.